Brookings Schaeffer on Health Policy
More from Brookings Schaeffer on Health Policy Blog
-
Understanding the Bipartisan Senate Finance Prescription Drug Reform Package
“USC-Brookings Schaeffer Initiative experts unpack the bipartisan Senate Finance prescription drug reform package.
-
California Saw Reduction in Out-of-Network Care from Affected Specialties after 2017 Surprise Billing Law
This blog presents new evidence on observed changes in provider network breadth after the implementation of California’s 2017 law.
-
Where Does Your State Stand in Texas vs. U.S.?
In Texas v. U.S., Texas and a number of other states have sued the federal government, arguing that the entire ACA should be struck down. So, where does your state stand in Texas v. U.S.?
Categorized in -
The Trump DOJ has Taken an Unexpected and Unworkable Position on the ACA
This piece describes the claim DOJ has made in regards to Texas v. U.S., attempts to unpack some of the complicated policy implications, and then considers the relevant legal issues.
Categorized in -
Considerations For Expanding International Reference Pricing Beyond Medicare Part B
Experts lay out considerations for expanding the administration’s proposed model beyond Medicare Part B drugs.
Categorized in -
What is Surprise Billing?
Experts from the USC-Brookings Schaeffer Initiative for Health Policy answer commonly asked questions about surprise medical bills and how to deal with them at a policy level.
Categorized in -
The Use of Vendors in Medicare Part B Drug Payment
USC-Brookings Schaeffer Initiative experts provide an analysis of a voluntary vendor approach for Medicare to restrain drug spending for Part B drugs.
Categorized in -
Rep. Ruiz’s Arbitration Proposal for Surprise Billing (H.R. 3502) Would Lead to Much Higher Costs and Deficits
USC-Brookings Schaeffer Initiative researchers review the latest proposed legislation from Representative Ruiz on surprise medical billing.
Categorized in -
CMS’s International Pricing Model for Medicare Part B Drugs: Implementation Issues
To lower the Part B portion of drug spending, the Trump Administration has proposed a demonstration project tying Medicare reimbursement for outpatient, physician-administered drugs to international prices. Paul Ginsburg and Steven Lieberman explore the potential consequences of such a rule.
Categorized in -
We Need More Primary Care Physicians: Here’s Why and How
USC-Brookings Schaeffer Initiative researchers explain why we need more primary care physicians and how to close the gap between primary care and specialty medicine.
Categorized in